Norepinephrine-P

Phase 3Small molecule

DDalian Municipal Central Hospital

Norepinephrine-P is one of 14 small molecule programs targeting General Anesthesia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

General AnesthesiaRecruiting

General AnesthesiaPhase 3

Recruiting

Competition

Competitive Landscape

19 competitors in General Anesthesia

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

7 2

Esmeron

Merck & Co.

Phase 3

3 3

Cypsedo

HHaisco-USA Pharmaceuticals, Inc.

Approved

1 4

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 5

Amidate

Pfizer

Phase 1

2 6

Norepinephrine-P

DDalian Municipal Central Hospital

Phase 3

1 7

Robinul

Jazz Pharmaceuticals

Preclinical

1 8

Carbocaine

Pfizer

Preclinical

1 9

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

2 10

Dexmedetomidine Hydrochloride

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

General Anesthesia1 trial

A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia

Recruiting·—·Phase 4·NCT06334549·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Norepinephrine-P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Norepinephrine-P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Norepinephrine-P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dalian Municipal Central Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDalian Municipal Central Hospital

Norepinephrine-P

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

General Anesthesia1 trial

References

Drug Info

Quick Facts

Related News